Shanghai Pharma Subsidiary's Ophthalmic Formula Cleared for Clinical Trials

Stock News07-20 16:13

An announcement has been issued by Shanghai Pharmaceuticals Holding Co.,Ltd. (SH: 601607) regarding a key development for one of its research projects.

The company's subsidiary, Shanghai Pharmaceutical Group Institute of Traditional Chinese Medicine Co., Ltd., has received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its new formulation, Qingrun Yangmu Granules.

This granule formulation was developed based on the Qingrun Yangmu Oral Liquid, a hospital preparation from the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, with modifications made to its preparation process and dosage form.

The research and development for this project was a collaborative effort involving the institute and the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, among other entities, with the core intellectual property rights held by the project team.

The planned clinical trials for this drug are intended to investigate its use in the treatment of dry eye disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195046148?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 16:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195046148","market":"hk","top_or_hot":-1,"title":"Shanghai Pharma Subsidiary's Ophthalmic Formula Cleared for Clinical Trials","media":"Stock News","content":"<p>An announcement has been issued by <b>Shanghai Pharmaceuticals Holding Co.,Ltd.</b> (<b>SH: 601607</b>) regarding a key development for one of its research projects.<br><br>The company's subsidiary, Shanghai Pharmaceutical Group Institute of Traditional Chinese Medicine Co., Ltd., has received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its new formulation, Qingrun Yangmu Granules.<br><br>This granule formulation was developed based on the Qingrun Yangmu Oral Liquid, a hospital preparation from the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, with modifications made to its preparation process and dosage form.<br><br>The research and development for this project was a collaborative effort involving the institute and the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, among other entities, with the core intellectual property rights held by the project team.<br><br>The planned clinical trials for this drug are intended to investigate its use in the treatment of dry eye disease.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharma Subsidiary's Ophthalmic Formula Cleared for Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharma Subsidiary's Ophthalmic Formula Cleared for Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-20 16:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>An announcement has been issued by <b>Shanghai Pharmaceuticals Holding Co.,Ltd.</b> (<b>SH: 601607</b>) regarding a key development for one of its research projects.<br><br>The company's subsidiary, Shanghai Pharmaceutical Group Institute of Traditional Chinese Medicine Co., Ltd., has received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its new formulation, Qingrun Yangmu Granules.<br><br>This granule formulation was developed based on the Qingrun Yangmu Oral Liquid, a hospital preparation from the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, with modifications made to its preparation process and dosage form.<br><br>The research and development for this project was a collaborative effort involving the institute and the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, among other entities, with the core intellectual property rights held by the project team.<br><br>The planned clinical trials for this drug are intended to investigate its use in the treatment of dry eye disease.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"","article_id":"1195046148","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195046148","pubTimestamp":1784535225,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"An announcement has been issued by Shanghai Pharmaceuticals Holding Co.,Ltd. (SH: 601607) regarding a key development for one of its research projects.The company's subsidiary, Shanghai...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0196":"行业龙头","BK0184":"上海国资改革","BK0028":"国家队","BK0097":"医药电商","BK0099":"上海本地重组","BMED":"iShares Health Innovation Active ETF","02607":"上海医药","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0209":"零售","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0175":"白马股","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK0187":"一线龙头"},"translate_title":"上海医药子公司眼科配方获批临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"IBBQ":1,"02607":1,"BMED":1},"content_text":"An announcement has been issued by Shanghai Pharmaceuticals Holding Co.,Ltd. (SH: 601607) regarding a key development for one of its research projects.The company's subsidiary, Shanghai Pharmaceutical Group Institute of Traditional Chinese Medicine Co., Ltd., has received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its new formulation, Qingrun Yangmu Granules.This granule formulation was developed based on the Qingrun Yangmu Oral Liquid, a hospital preparation from the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, with modifications made to its preparation process and dosage form.The research and development for this project was a collaborative effort involving the institute and the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, among other entities, with the core intellectual property rights held by the project team.The planned clinical trials for this drug are intended to investigate its use in the treatment of dry eye disease.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195046148","isCrawlerRequest":true}